On the public citation graph

Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants

https://doi.org/10.1056/nejmoa2110275
0 signed · 1049 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/j.vaccine.2012.11.097openalex-snapshot
Number-needed-to-vaccinate calculations: Fallacies associated with exclusion of transmission
inferredcites →https://doi.org/10.1016/j.vaccine.2014.12.033openalex-snapshot
How and why researchers use the number needed to vaccinate to inform decision making—A systematic review
inferredcites →https://doi.org/10.1016/j.vaccine.2018.02.088openalex-snapshot
Vaccine-preventable disease incidence of pneumococcal conjugate vaccine in the Finnish invasive pneumococcal disease vaccine trial
inferredcites →https://doi.org/10.1016/j.vaccine.2020.06.034openalex-snapshot
Number needed to immunize to prevent RSV with extended half-life monoclonal antibody
inferredcites →https://doi.org/10.1016/s0022-3476(99)70085-5openalex-snapshot
Respiratory illness after severe respiratory syncytial virus disease in infancy in The Gambia
inferredcites →https://doi.org/10.1016/s0140-6736(10)60206-1openalex-snapshot
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis
inferredcites →https://doi.org/10.1016/s0140-6736(17)30938-8openalex-snapshot
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study
inferredcites →https://doi.org/10.1016/s0140-6736(88)92052-1openalex-snapshot
NATIONAL INSTITUTE OF COMMUNICABLE DISEASES
inferredcites →https://doi.org/10.1016/s2214-109x(20)30251-5openalex-snapshot
Early-life respiratory syncytial virus lower respiratory tract infection in a South African birth cohort: epidemiology and effect on lung health
inferredcites →https://doi.org/10.1056/nejmoa1908380openalex-snapshot
Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants
inferredcites →https://doi.org/10.1056/nejmoa1913556openalex-snapshot
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
inferredcites →https://doi.org/10.1097/inf.0000000000001916openalex-snapshot
Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants
inferredcites →https://doi.org/10.1111/j.1524-4733.2009.00534.xopenalex-snapshot
Budget Impact and Cost-Effectiveness of Including a Pentavalent Rotavirus Vaccine in the New Zealand Childhood Immunization Schedule
inferredcites →https://doi.org/10.1126/scitranslmed.aaj1928openalex-snapshot
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
inferredcites →https://doi.org/10.1542/peds.2007-0167openalex-snapshot
Childhood Influenza: Number Needed to Vaccinate to Prevent 1 Hospitalization or Outpatient Visit
inferredcites →https://doi.org/10.1542/peds.2013-0303openalex-snapshot
Respiratory Syncytial Virus–Associated Hospitalizations Among Children Less Than 24 Months of Age
inferredcites →https://doi.org/10.1542/peds.2014-1665openalex-snapshot
Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
inferredcites →https://doi.org/10.2807/1560-7917.es.2021.26.29.2001600openalex-snapshot
Decline of influenza and respiratory syncytial virus detection in facility-based surveillance during the COVID-19 pandemic, South Africa, January to October 2020
inferredcites →https://doi.org/10.7189/jogh.05.020416openalex-snapshot
Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: Systematic review and meta–analysis

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4749763openalex-extracted
inferred← citeshttps://doi.org/10.2139/ssrn.4797655openalex-extracted
inferred← citeshttps://doi.org/10.2139/ssrn.4894819openalex-extracted
Genotypic and Phenotypic Characterisation of Rsv after Nirsevimab Breakthrough Infections in a Large Multicentre Observational Real-World Study
inferred← citeshttps://doi.org/10.1001/jama.2024.7406openalex-snapshot
Therapies to Decrease Severe Respiratory Syncytial Virus Illness
inferred← citeshttps://doi.org/10.1001/jama.2025.24082openalex-snapshot
Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus–Related Hospitalization in Newborns
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2023.0023openalex-snapshot
Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2023.28950openalex-snapshot
Infants Admitted to US Intensive Care Units for RSV Infection During the 2022 Seasonal Peak
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2024.19268openalex-snapshot
Nonadjuvanted Bivalent Respiratory Syncytial Virus Vaccination and Perinatal Outcomes
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2024.40997openalex-snapshot
Respiratory Syncytial Virus and US Pediatric Intensive Care Utilization
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2024.60735openalex-snapshot
Respiratory Syncytial Virus Vaccine and Nirsevimab Uptake Among Pregnant People and Their Neonates
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2025.0380openalex-snapshot
Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2025.14622openalex-snapshot
Scenario Projections of Respiratory Syncytial Virus Hospitalizations Averted Due to New Immunizations
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2025.22779openalex-snapshot
Optimizing Timing for Respiratory Syncytial Virus Prevention Interventions for Infants
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2025.4341openalex-snapshot
Sociodemographic Characteristics of Infants Receiving Nirsevimab
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2025.44679openalex-snapshot
Nirsevimab Prophylaxis and Respiratory Syncytial Virus Hospitalizations Among Infants
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2025.4666openalex-snapshot
Risk Factors for Severe Disease Among Children Hospitalized With Respiratory Syncytial Virus
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2026.6042openalex-snapshot
Nirsevimab in High-Risk Infants in a Respiratory Syncytial Virus Prevention Strategy
inferred← citeshttps://doi.org/10.1001/jamapediatrics.2025.5280openalex-snapshot
Nirsevimab Against Hospitalizations and Emergency Department Visits for Lower Respiratory Tract Infection in Infants
inferred← citeshttps://doi.org/10.1001/jamapediatrics.2026.0657openalex-snapshot
Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations
inferred← citeshttps://doi.org/10.1001/jamapediatrics.2026.1346openalex-snapshot
Dual Immunization Against RSV With RSVpreF and Nirsevimab
inferred← citeshttps://doi.org/10.1001/jamapediatrics.2026.2760openalex-snapshot
Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons
inferred← citeshttps://doi.org/10.1002/14651858.cd009417.pub3openalex-snapshot
Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection
inferred← citeshttps://doi.org/10.1002/9781683670438.mcm0089openalex-snapshot
Respiratory Syncytial Virus and Human Metapneumovirus
inferred← citeshttps://doi.org/10.1002/9781683674849.mcm0089openalex-snapshot
Respiratory Syncytial Virus and Human Metapneumovirus
inferred← citeshttps://doi.org/10.1002/9783527845088.ch09openalex-snapshot
Presatovir: A Once‐daily Oral Respiratory Syncytial Virus Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus Infection in Adults and Infants
inferred← citeshttps://doi.org/10.1002/advs.202306729openalex-snapshot
Inhaled “Muco‐Trapping” Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections
inferred← citeshttps://doi.org/10.1002/advs.202402975openalex-snapshot
Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2
inferred← citeshttps://doi.org/10.1002/cbic.202300831openalex-snapshot
Therapeutic Peptides, Proteins and their Nanostructures for Drug Delivery and Precision Medicine
inferred← citeshttps://doi.org/10.1002/cpt.70199openalex-snapshot
Population Pharmacokinetics of Clesrovimab in Preterm and Full‐Term Infants
inferred← citeshttps://doi.org/10.1002/eji.202451309openalex-snapshot
RSV‐Induced Regulation of DC via H3K4 Demethylase KDM5b
inferred← citeshttps://doi.org/10.1002/iid3.70420openalex-snapshot
Burden and Characteristics of Respiratory Syncytial Virus‐Associated Bronchiolitis in Hospitalized Infants in Italy: A Systematic Review
inferred← citeshttps://doi.org/10.1002/ijgo.71286openalex-snapshot
From policy to practice: Systemic solutions to strengthen maternal immunization in sub‐Saharan Africa
inferred← citeshttps://doi.org/10.1002/jcph.2401openalex-snapshot
Population Pharmacokinetics of Nirsevimab in Preterm and Term Infants
inferred← citeshttps://doi.org/10.1002/jgf2.70131openalex-snapshot
β‐Lactamase‐Producing Haemophilus influenzae Pneumonia in a 1‐Month‐Old Infant With Respiratory Syncytial Virus Bronchiolitis
inferred← citeshttps://doi.org/10.1002/jhm.70206openalex-snapshot
Clinical progress note: Respiratory syncytial virus
inferred← citeshttps://doi.org/10.1002/jmv.29116openalex-snapshot
Seasonality and risk factor analysis of respiratory syncytial virus infection in children in Taiwan—A retrospective study from 1995 to 2005
inferred← citeshttps://doi.org/10.1002/jmv.29453openalex-snapshot
Respiratory syncytial virus immunoprophylaxis: Novel opportunities and a call for equity
inferred← citeshttps://doi.org/10.1002/jmv.29483openalex-snapshot
First RSV epidemic with nirsevimab. Older children than previous epidemics, even when hospitalized
inferred← citeshttps://doi.org/10.1002/jmv.29719openalex-snapshot
Timing patterns of initial respiratory syncytial virus infection and factors influencing disease severity in hospitalized infants with different health status
inferred← citeshttps://doi.org/10.1002/jmv.70006openalex-snapshot
Burden and seasonality of RSV bronchiolitis in hospitalized children on a French Caribbean island: Practical lessons from a 13‐year study
inferred← citeshttps://doi.org/10.1002/jmv.70658openalex-snapshot
Rebound of Respiratory Virus Activity and Seasonality to Pre‐Pandemic Patterns
inferred← citeshttps://doi.org/10.1002/jmv.70662openalex-snapshot
Real‐World Effectiveness of Nirsevimab in Preventing RSV Hospitalizations: Evidence of Protection in Southern Italian Infants, 2024–2025
inferred← citeshttps://doi.org/10.1002/jmv.71089openalex-snapshot
Post‐Pandemic Resurgence of Respiratory Syncytial Virus in Thailand: Molecular Epidemiology and Sublineage Turnover Among Children, 2023–2025
inferred← citeshttps://doi.org/10.1002/jmv.71137openalex-snapshot
Epidemiological Profiles of Respiratory Syncytial Virus Infection Among Hospitalized Children in a Tropical Setting: A Large Laboratory‐Based Surveillance Study From Hainan, China
inferred← citeshttps://doi.org/10.1002/mco2.70403openalex-snapshot
Molecular and Cellular Mechanisms of Respiratory Syncytial Viral Infection: Its Implications for Prophylactic and Therapeutic Pharmaceuticals
inferred← citeshttps://doi.org/10.1002/med.70025openalex-snapshot
Respiratory Syncytial Virus (RSV): A Comprehensive Overview From Basic Biology to Clinical Prevention and Control
inferred← citeshttps://doi.org/10.1002/ped4.12377openalex-snapshot
Nirsevimab brings breakthrough in the prevention of respiratory syncytial virus infection in infants – Importance of design
inferred← citeshttps://doi.org/10.1002/ped4.70075openalex-snapshot
Long‐acting monoclonal antibodies and the evolving landscape of infant respiratory syncytial virus prevention
inferred← citeshttps://doi.org/10.1002/ppul.26370openalex-snapshot
RSV through the COVID‐19 pandemic: Burden, shifting epidemiology, and implications for the future
inferred← citeshttps://doi.org/10.1002/ppul.26434openalex-snapshot
Pediatric respiratory admissions and related viral infections during the COVID‐19 pandemic
inferred← citeshttps://doi.org/10.1002/ppul.26460openalex-snapshot
Impact of the publication of the Italian guidelines for bronchiolitis on the management of hospitalized children in Pisa, Italy
inferred← citeshttps://doi.org/10.1002/ppul.26474openalex-snapshot
KEYNOTE LECTURE
inferred← citeshttps://doi.org/10.1002/ppul.26920openalex-snapshot
Exploratory analysis of the economically justifiable price of nirsevimab for healthy late‐preterm and term infants in Colombia
inferred← citeshttps://doi.org/10.1002/ppul.27041openalex-snapshot
Monoclonal antibody therapies in respiratory syncytial virus prophylaxis—An umbrella review
inferred← citeshttps://doi.org/10.1002/ppul.71215openalex-snapshot
Viral Bronchiolitis in Infants in the Era of Targeted Therapies: What Now and What's Next?
inferred← citeshttps://doi.org/10.1002/ppul.71302openalex-snapshot
Hospitalizations in Infants and Young Children With Cystic Fibrosis Enrolled in Medicaid
inferred← citeshttps://doi.org/10.1002/ppul.71451openalex-snapshot
Effect of Nirsevimab as a Primary Preventive Strategy on the Incidence, Severity, and Viral Etiology of Bronchiolitis: A Four‐Year Observational Study
inferred← citeshttps://doi.org/10.1002/ppul.71456openalex-snapshot
The Persistent Respiratory Impact of Respiratory Syncytial Virus (RSV) Bronchiolitis in Infants
inferred← citeshttps://doi.org/10.1002/ppul.71563openalex-snapshot
Findings From Long‐Term Follow‐up in Children Hospitalized for Bronchiolitis in Pisa: Is It Time for a Standardized Protocol?
inferred← citeshttps://doi.org/10.1002/ppul.71647openalex-snapshot
Virus Detection and Hospitalization Rate in Infants With Bronchiolitis After Nirsevimab Introduction: A Retrospective Comparative Two‐Season Study
inferred← citeshttps://doi.org/10.1002/ppul.71689openalex-snapshot
Impact of RSV Preventive Strategies on Hospitalizations for Bronchiolitis in Infants
inferred← citeshttps://doi.org/10.1002/ppul.71853openalex-snapshot
From Selective Prophylaxis to Broad Infant RSV Protection: A Bibliometric Analysis and Evidence Gap Map, 1998–2025
inferred← citeshttps://doi.org/10.1002/rmv.2576openalex-snapshot
Systematic Review of the Efficacy and Safety of RSV‐Specific Monoclonal Antibodies and Antivirals in Development
inferred← citeshttps://doi.org/10.1002/rmv.70003openalex-snapshot
An Overview on Disease Burden and Management of Respiratory Syncytial Virus Infections in Older Adults in the Asia‐Pacific Region
inferred← citeshttps://doi.org/10.1002/rmv.70071openalex-snapshot
Landscape of Prophylactic Strategies Against Human Parainfluenza Virus Type 3
inferred← citeshttps://doi.org/10.1007/978-1-0716-4666-3_1openalex-snapshot
Introduction to Respiratory Syncytial Virus
inferred← citeshttps://doi.org/10.1007/978-3-031-41542-5_19openalex-snapshot
Update in Pediatric Infectious Disease
inferred← citeshttps://doi.org/10.1007/978-3-031-84089-0_11openalex-snapshot
Community-Acquired Pneumonia
inferred← citeshttps://doi.org/10.1007/978-3-031-86129-1_31openalex-snapshot
Immunizations in the Nursery
inferred← citeshttps://doi.org/10.1007/s00018-026-06265-3openalex-snapshot
ZFP91 restricts RSV replication by driving K48-linked ubiquitination and proteasomal degradation of M2-1
inferred← citeshttps://doi.org/10.1007/s00063-023-01050-7openalex-snapshot
Respiratorische Virusinfektionen
inferred← citeshttps://doi.org/10.1007/s00112-024-01952-6openalex-snapshot
Prävention von Infektionen mit dem respiratorischen Synzytialvirus im Kindesalter
inferred← citeshttps://doi.org/10.1007/s00210-024-03063-1openalex-snapshot
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023
inferred← citeshttps://doi.org/10.1007/s00246-023-03388-3openalex-snapshot
Improving Palivizumab Administration to High-Risk Infants with Heart Disease via a Communication-Based Quality Improvement Initiative
inferred← citeshttps://doi.org/10.1007/s00431-022-04698-zopenalex-snapshot
The burden and surveillance of RSV disease in young children in Belgium—expert opinion
inferred← citeshttps://doi.org/10.1007/s00431-023-05201-yopenalex-snapshot
Respiratory syncytial virus: can we still believe that after pandemic bronchiolitis is not a critical issue for public health?
inferred← citeshttps://doi.org/10.1007/s00431-024-05530-6openalex-snapshot
Management and outcomes of bronchiolitis in Italy and Latin America: a multi-center, prospective, observational study
inferred← citeshttps://doi.org/10.1007/s00431-024-05634-zopenalex-snapshot
Impact of universal immunization program with monoclonal antibody nirsevimab on reducing the burden of serious bronchiolitis that need pediatric intensive care
inferred← citeshttps://doi.org/10.1007/s00431-024-05779-xopenalex-snapshot
Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season
inferred← citeshttps://doi.org/10.1007/s00431-024-05785-zopenalex-snapshot
Postpandemic fluctuations of regional respiratory syncytial virus hospitalization epidemiology: potential impact on an immunization program in Switzerland
inferred← citeshttps://doi.org/10.1007/s00431-025-06125-5openalex-snapshot
Universal administration of nirsevimab in infants: an analysis of hospitalisations and paediatric intensive care unit admissions for RSV-associated lower respiratory tract infections
inferred← citeshttps://doi.org/10.1007/s00431-025-06448-3openalex-snapshot
Impact of universal nirsevimab prophylaxis on clinical and ultrasound presentations of lower respiratory tract infections in hospitalized pediatric patients
inferred← citeshttps://doi.org/10.1007/s00431-025-06581-zopenalex-snapshot
Adherence to the nirsevimab immunization campaign: analysis of sociodemographic and medico-economic influences—single-centre prospective cohort study in France
inferred← citeshttps://doi.org/10.1007/s00431-026-06746-4openalex-snapshot
Real-world impact of nirsevimab on the epidemiology and severity of pediatric respiratory syncytial virus infections: a three-season cohort study in Italy
inferred← citeshttps://doi.org/10.1007/s00431-026-07508-yopenalex-snapshot
Nirsevimab reduced acute otitis media infections in infants—a nationwide interrupted time-series analysis
inferred← citeshttps://doi.org/10.1007/s00608-024-01224-2openalex-snapshot
Empfehlungen der Österreichischen Gesellschaft für Kinder- und Jugendheilkunde zur Prophylaxe einer RSV-Infektion mit Nirsevimab
inferred← citeshttps://doi.org/10.1007/s00608-025-01325-6openalex-snapshot
RSV-Prophylaxe in der Herbst-Winter-Saison 2025/26 durch passive Immunisierung von Neugeborenen und Säuglingen mit Nirsevimab
inferred← citeshttps://doi.org/10.1007/s10405-025-00639-3openalex-snapshot
Update: Respiratorische Viren – SARS-CoV-2, respiratorisches Synzytialvirus, Influenza‑, Rhino-, humanes Metapneumo- und Bocavirus
inferred← citeshttps://doi.org/10.1007/s12026-025-09732-4openalex-snapshot
Maternal RSV vaccine: a systematic review and meta-analysis of immunogenicity and perinatal safety
inferred← citeshttps://doi.org/10.1007/s12098-023-04613-wopenalex-snapshot
Respiratory Syncytial Virus Infection: An Update
inferred← citeshttps://doi.org/10.1007/s12325-024-02798-wopenalex-snapshot
Respiratory Syncytial Virus (RSV) Burden in Infants in the Kingdom of Saudi Arabia and the Impact of All-Infant RSV Protection: A Modeling Study
inferred← citeshttps://doi.org/10.1007/s12519-023-00777-9openalex-snapshot
Expert consensus on the diagnosis, treatment, and prevention of respiratory syncytial virus infections in children
inferred← citeshttps://doi.org/10.1007/s12519-025-00926-2openalex-snapshot
Expert consensus on the burden of respiratory syncytial virus disease and the utility of nirsevimab for disease prevention and protection of infants
inferred← citeshttps://doi.org/10.1007/s12519-025-00997-1openalex-snapshot
Position statement of the Mexican Association of Pediatrics on the immunoprevention of respiratory syncytial virus infection during pregnancy and infancy
inferred← citeshttps://doi.org/10.1007/s13312-026-00385-6openalex-snapshot
Nirsevimab Implementation and Primary Management of Lower Respiratory Tract Infections in Infants in Spain: A Quasi-Experimental Study
inferred← citeshttps://doi.org/10.1007/s13346-025-01909-6openalex-snapshot
Inhaled biologics for respiratory diseases: clinical potential and emerging technologies
inferred← citeshttps://doi.org/10.1007/s15010-024-02391-xopenalex-snapshot
Clinical and economic inpatient burden of respiratory syncytial virus (RSV) infections in children < 2 years of age in Germany, 2014–2019: a retrospective health claims analysis
inferred← citeshttps://doi.org/10.1007/s15010-025-02654-1openalex-snapshot
Changes in RSV-associated lower respiratory tract infections among hospitalized and outpatient children under 2 years in Northern Bavaria after general recommendation of Nirsevimab immunization in 2024
inferred← citeshttps://doi.org/10.1007/s40121-022-00737-2openalex-snapshot
Preventing Respiratory Syncytial Virus in Children in France: A Narrative Review of the Importance of a Reinforced Partnership Between Parents, Healthcare Professionals, and Public Health Authorities
inferred← citeshttps://doi.org/10.1007/s40121-024-00970-xopenalex-snapshot
Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials
inferred← citeshttps://doi.org/10.1007/s40121-024-01058-2openalex-snapshot
Respiratory Syncytial Virus Risk Profile in Hospitalized Infants and Comparison with Influenza and COVID-19 Controls in Valladolid, Spain, 2010–2022
inferred← citeshttps://doi.org/10.1007/s40121-025-01134-1openalex-snapshot
Cost-Effectiveness and Public Health Impact of Universal Prophylaxis with Nirsevimab Against Respiratory Syncytial Virus (RSV) Infections in all Infants in Japan
inferred← citeshttps://doi.org/10.1007/s40121-025-01194-3openalex-snapshot
Estimating the Public Health and Economic Impact of Immunisation with Nirsevimab or Maternal Immunisation for the Prevention of RSV-Related Outcomes Over Infants’ First RSV Season in the UK
inferred← citeshttps://doi.org/10.1007/s40121-025-01214-2openalex-snapshot
Preferences of Dutch Parents and Expectant Parents for Respiratory Syncytial Virus Prevention Strategies: A Discrete Choice Experiment
inferred← citeshttps://doi.org/10.1007/s40121-026-01299-3openalex-snapshot
Taxonomy of the Full Health and Societal Value of Maternal Vaccination to Prevent Infant Respiratory Syncytial Virus Disease
inferred← citeshttps://doi.org/10.1007/s40121-026-01311-wopenalex-snapshot
Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study
inferred← citeshttps://doi.org/10.1007/s40121-026-01344-1openalex-snapshot
Cost-Effectiveness of Alternative Immunization Strategies to Protect Infants Against Respiratory Syncytial Virus in Germany: A Decision Modeling Study
inferred← citeshttps://doi.org/10.1007/s40121-026-01382-9openalex-snapshot
Analysis of the Economic and Public Health Impact of New Immunization Strategies in Infants Against Respiratory Syncytial Virus (RSV) in Colombia
inferred← citeshttps://doi.org/10.1007/s40121-026-01442-0openalex-snapshot
Detection of a Nirsevimab-Resistant RSV-B Variant (F:K68Q) in an Adult with Severe Infection
inferred← citeshttps://doi.org/10.1007/s40258-026-01063-1openalex-snapshot
Cost-Effectiveness of Maternal RSVpreF Vaccination Compared with Newborn Nirsevimab RSV Prophylaxis or No RSV Prophylaxis in Switzerland
inferred← citeshttps://doi.org/10.1007/s40259-023-00596-4openalex-snapshot
Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus
inferred← citeshttps://doi.org/10.1007/s40265-022-01829-6openalex-snapshot
Nirsevimab: First Approval
inferred← citeshttps://doi.org/10.1007/s40265-026-02348-4openalex-snapshot
Recaticimab: The First Fc-Engineered PCSK9 Monoclonal Antibody for More Long-Lasting Effect in Lipid Lowering
inferred← citeshttps://doi.org/10.1007/s40267-023-01039-4openalex-snapshot
Nirsevimab in the prevention of respiratory syncytial virus lower respiratory tract disease: a profile of its use
inferred← citeshttps://doi.org/10.1007/s40267-025-01157-1openalex-snapshot
Effective treatments for respiratory syncytial virus infection in children remain elusive but prevention tools are now available
inferred← citeshttps://doi.org/10.1007/s40272-023-00606-6openalex-snapshot
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date
inferred← citeshttps://doi.org/10.1007/s40272-024-00625-xopenalex-snapshot
CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus
inferred← citeshttps://doi.org/10.1007/s40273-025-01469-0openalex-snapshot
Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant Protection
inferred← citeshttps://doi.org/10.1007/s40273-026-01601-8openalex-snapshot
Cost-Effectiveness of Immunising Interventions to Reduce Respiratory Syncytial Virus Disease Burden in Infants in Australia
inferred← citeshttps://doi.org/10.1007/s40588-025-00245-0openalex-snapshot
Prophylaxis of RSV Infection in Infants
inferred← citeshttps://doi.org/10.1007/s40746-025-00334-8openalex-snapshot
Recent Advances in the Management of Bronchopulmonary Dysplasia
inferred← citeshttps://doi.org/10.1007/s44332-025-00064-xopenalex-snapshot
RSV in der Rheumatologie: Klinische Relevanz und neue Impfstoffe
inferred← citeshttps://doi.org/10.1016/b978-0-323-79058-1.00052-9openalex-snapshot
Respiratory Syncytial Virus Vaccines and Monoclonal Antibodies
inferred← citeshttps://doi.org/10.1016/b978-0-323-79525-8.00050-0openalex-snapshot
Prevention of fetal and early life infections through maternal-neonatal immunization
inferred← citeshttps://doi.org/10.1016/b978-0-443-36518-8.00016-3openalex-snapshot
Innovative antiviral strategies: Clinical advances in respiratory syncytial virus inhibitor development
inferred← citeshttps://doi.org/10.1016/b978-3-437-23817-8.00050-1openalex-snapshot
RSV
inferred← citeshttps://doi.org/10.1016/bs.aivir.2023.05.002openalex-snapshot
Advanced fluorescence microscopy in respiratory virus cell biology
inferred← citeshttps://doi.org/10.1016/bs.aivir.2023.06.001openalex-snapshot
Spatial resolution of virus replication: RSV and cytoplasmic inclusion bodies
inferred← citeshttps://doi.org/10.1016/j.ajog.2023.10.046openalex-snapshot
Society for Maternal-Fetal Medicine Statement: Clinical considerations for the prevention of respiratory syncytial virus disease in infants
inferred← citeshttps://doi.org/10.1016/j.ajogmf.2026.101947openalex-snapshot
Viral illness and neonatal outcomes in neonates exposed to in utero respiratory syncytial virus vaccination vs postnatal nirsevimab
inferred← citeshttps://doi.org/10.1016/j.annepidem.2024.04.010openalex-snapshot
Trends in RSV testing patterns among infants presenting with bronchiolitis: Results from four United States health systems, 2015-2023
inferred← citeshttps://doi.org/10.1016/j.anpede.2022.11.002openalex-snapshot
Immunisation schedule of the Spanish Association of Paediatrics: 2023 Recommendations
inferred← citeshttps://doi.org/10.1016/j.anpede.2023.09.005openalex-snapshot
Recommendations of the Spanish Society of Neonatology for the prevention of severe respiratory syncytial virus infections with nirsevimab, for the 2023–2024 season
inferred← citeshttps://doi.org/10.1016/j.anpede.2023.09.006openalex-snapshot
Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP)
inferred← citeshttps://doi.org/10.1016/j.anpede.2023.12.003openalex-snapshot
Immunisation schedule of the Spanish Association of Pediatrics: 2024 recommendations
inferred← citeshttps://doi.org/10.1016/j.anpedi.2022.10.002openalex-snapshot
Calendario de inmunizaciones de la Asociación Española de Pediatría: recomendaciones 2023
inferred← citeshttps://doi.org/10.1016/j.anpedi.2023.09.001openalex-snapshot
Recomendaciones de la Sociedad Española de Neonatología para la profilaxis frente a las infecciones graves por virus respiratorio sincitial con nirsevimab, para la estación 2023-2024
inferred← citeshttps://doi.org/10.1016/j.anpedi.2023.09.006openalex-snapshot
Nirsevimab para la prevención de la enfermedad por virus respiratorio sincitial en niños. Posicionamiento de la Sociedad Española de Infectología Pediátrica
inferred← citeshttps://doi.org/10.1016/j.anpedi.2023.12.001openalex-snapshot
Calendario de inmunizaciones de la Asociación Española de Pediatría: recomendaciones 2024
inferred← citeshttps://doi.org/10.1016/j.antiviral.2023.105734openalex-snapshot
Mechanisms of antiviral activity of the new hDHODH inhibitor MEDS433 against respiratory syncytial virus replication
inferred← citeshttps://doi.org/10.1016/j.antiviral.2023.105783openalex-snapshot
A molecular perspective for the development of antibodies against the human respiratory syncytial virus
inferred← citeshttps://doi.org/10.1016/j.antiviral.2023.105791openalex-snapshot
Current state and challenges in respiratory syncytial virus drug discovery and development
inferred← citeshttps://doi.org/10.1016/j.antiviral.2025.106298openalex-snapshot
Mapping the impact of 1′-, 2′- and 4′-nucleotide modifications on the Respiratory Syncytial Virus RNA-dependent RNA polymerase
inferred← citeshttps://doi.org/10.1016/j.antiviral.2026.106473openalex-snapshot
The anti-respiratory syncytial virus activity of biochemicals from Pyrola incarnata
inferred← citeshttps://doi.org/10.1016/j.aprim.2023.102674openalex-snapshot
Estrategia vacunal en las virasis hibernales: presente y futuro
inferred← citeshttps://doi.org/10.1016/j.apsb.2025.02.015openalex-snapshot
Advances in development of antiviral strategies against respiratory syncytial virus
inferred← citeshttps://doi.org/10.1016/j.arbres.2023.06.006openalex-snapshot
The Path Towards Effective Respiratory Syncytial Virus Immunization Policies: Recommended Actions
inferred← citeshttps://doi.org/10.1016/j.arbres.2024.05.026openalex-snapshot
New Vaccines for Chronic Respiratory Patients
inferred← citeshttps://doi.org/10.1016/j.arbres.2025.06.010openalex-snapshot
Early Nirsevimab Administration During Hospitalization for RSV Bronchiolitis may Reduce Disease Severity in Non-immunized infants: A Descriptive Study
inferred← citeshttps://doi.org/10.1016/j.arbres.2026.01.009openalex-snapshot
Respiratory Syncytial Virus in Pediatrics: Update on Epidemiology, Management, Long-term Consequences and Prevention. Consensus From Asociación Latinoamericana de Tórax (ALAT) 2025
inferred← citeshttps://doi.org/10.1016/j.arcped.2026.105581openalex-snapshot
Clinical characteristics and co-infection patterns of human metapneumovirus infection in children under 5 years of age
inferred← citeshttps://doi.org/10.1016/j.banm.2023.11.016openalex-snapshot
Le virus respiratoire syncytial et sa prévention en 2024
inferred← citeshttps://doi.org/10.1016/j.bjid.2023.103702openalex-snapshot
Comparative analysis of Respiratory Syncytial Virus frequency rates and viral load in different patient cohorts in a University Hospital in São Paulo, Brazil, over an eight-year period (2005–2013)
inferred← citeshttps://doi.org/10.1016/j.btre.2024.e00856openalex-snapshot
Characterization of host cell proteins in the downstream process of plant-Based biologics using LC-MS profiling
inferred← citeshttps://doi.org/10.1016/j.bulcan.2024.10.013openalex-snapshot
Vaccination des enfants et adolescents traités pour une leucémie aiguë, hors allogreffés : recommandations du comité leucémies de la Société française de lutte contre les cancers et les leucémies de l’enfant et de l’adolescent (SFCE)
inferred← citeshttps://doi.org/10.1016/j.cahpu.2024.07.003openalex-snapshot
Prévention des infections à VRS : un état des lieux
inferred← citeshttps://doi.org/10.1016/j.cegh.2026.102371openalex-snapshot
Use of Nirsevimab for Respiratory Syncytial Virus (RSV) prevention in India: current status and way forward
inferred← citeshttps://doi.org/10.1016/j.cellimm.2024.104824openalex-snapshot
Development of innate and adaptive immunity to RSV in young children
inferred← citeshttps://doi.org/10.1016/j.celrep.2024.114811openalex-snapshot
Targeting RSV-neutralizing B cell receptors with anti-idiotypic antibodies
inferred← citeshttps://doi.org/10.1016/j.chom.2023.07.002openalex-snapshot
Potent cross-neutralization of respiratory syncytial virus and human metapneumovirus through a structurally conserved antibody recognition mode
inferred← citeshttps://doi.org/10.1016/j.clp.2024.10.007openalex-snapshot
Transplacental Antibodies
inferred← citeshttps://doi.org/10.1016/j.cmi.2023.08.028openalex-snapshot
Respiratory syncytial virus in adults with comorbidities: an update on epidemiology, vaccines, and treatments
inferred← citeshttps://doi.org/10.1016/j.cmi.2024.03.014openalex-snapshot
Women's acceptance of two strategies for preventing respiratory syncytial virus infant bronchiolitis: maternal immunization or monoclonal antibodies for newborns
inferred← citeshttps://doi.org/10.1016/j.cytogfr.2022.10.001openalex-snapshot
Development of mRNA vaccines against respiratory syncytial virus (RSV)
inferred← citeshttps://doi.org/10.1016/j.drudis.2025.104364openalex-snapshot
An overview of progress in human metapneumovirus (hMPV) research: Structure, function, and therapeutic opportunities
inferred← citeshttps://doi.org/10.1016/j.earlhumdev.2022.105666openalex-snapshot
New strategies for the prevention of respiratory syncytial virus (RSV)
inferred← citeshttps://doi.org/10.1016/j.ebiom.2024.105044openalex-snapshot
Differential anti-viral response to respiratory syncytial virus A in preterm and term infants
inferred← citeshttps://doi.org/10.1016/j.ebiom.2024.105318openalex-snapshot
The role of respiratory syncytial virus G protein in immune cell infection and pathogenesis
inferred← citeshttps://doi.org/10.1016/j.ebiom.2025.106104openalex-snapshot
Preclinical characterisation of the protective capacity of an anti-nucleoprotein hRSV monoclonal antibody
inferred← citeshttps://doi.org/10.1016/j.eclinm.2024.102790openalex-snapshot
An evaluation of 2015–2019 United States respiratory syncytial virus hospitalizations as a framework to develop potential strategies for the preventiosn of the hospital burden among infants
inferred← citeshttps://doi.org/10.1016/j.eclinm.2024.102986openalex-snapshot
Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: a prospective longitudinal cohort study in France
inferred← citeshttps://doi.org/10.1016/j.eclinm.2025.103281openalex-snapshot
Real-world uptake of nirsevimab, RSV maternal vaccine, and RSV vaccines for older adults: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.eclinm.2025.103352openalex-snapshot
Global outbreaks of respiratory syncytial virus infections from 1960 to 2025: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.eclinm.2026.103837openalex-snapshot
The prevalence and role of human respiratory syncytial virus in pediatric respiratory tract infections: a systematic review and meta-analysis of global data
inferred← citeshttps://doi.org/10.1016/j.eclinm.2026.104017openalex-snapshot
Efficacy and effectiveness of long-acting monoclonal antibodies and vaccines against RSV: a systematic review and meta-analysis of studies from 2018 to 2025
inferred← citeshttps://doi.org/10.1016/j.eclinm.2026.104219openalex-snapshot
Regional inequality in infant RSV morbidity and mortality burden in the era of expanded RSV passive immunisation: a global projection modelling study
inferred← citeshttps://doi.org/10.1016/j.eimc.2023.01.001openalex-snapshot
Respiratory syncytial virus infection in COVID-19 times: Trick or threat?
inferred← citeshttps://doi.org/10.1016/j.eimc.2024.04.010openalex-snapshot
Impacto de la inmunización con nirsevimab en las infecciones por VRS atendidas en urgencias pediátricas: primeros resultados en un hospital terciario de Madrid
inferred← citeshttps://doi.org/10.1016/j.eimc.2024.07.007openalex-snapshot
Análisis comparativo de las infecciones respiratorias agudas de etiología viral en menores de 6 meses con y sin nirsevimab en Baleares (2022-2023 y 2023-2024)
inferred← citeshttps://doi.org/10.1016/j.eimc.2024.11.007openalex-snapshot
Impacto de la campaña de inmunización pasiva con nirsevimab en 2023-24 en Castellón. Resultados finales
inferred← citeshttps://doi.org/10.1016/j.eimc.2025.03.006openalex-snapshot
Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department
inferred← citeshttps://doi.org/10.1016/j.eimc.2026.503138openalex-snapshot
Impacto de la inmunización con nirsevimab en los ingresos de un hospital de tercer nivel
inferred← citeshttps://doi.org/10.1016/j.eimce.2023.01.006openalex-snapshot
Respiratory syncytial virus infection in COVID-19 times: Trick or threat?
inferred← citeshttps://doi.org/10.1016/j.eimce.2024.04.014openalex-snapshot
Impact of nirsevimab immunization on RSV infections attended in the pediatric emergency department: First results in a tertiary hospital in Madrid
inferred← citeshttps://doi.org/10.1016/j.eimce.2024.10.002openalex-snapshot
Comparative analysis of acute respiratory infections of viral etiology in children under 6 months with and without nirsevimab in the Balearic Islands (2022–2023 and 2023–2024)
inferred← citeshttps://doi.org/10.1016/j.eimce.2025.01.006openalex-snapshot
Impact of the passive immunization campaign with nirsevimab in 2023–24 in Castellón. Final results
inferred← citeshttps://doi.org/10.1016/j.eimce.2025.03.017openalex-snapshot
Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department
inferred← citeshttps://doi.org/10.1016/j.eimce.2026.503138openalex-snapshot
Impact of nirsevimab immunization on admissions at a tertiary hospital
inferred← citeshttps://doi.org/10.1016/j.ejmech.2026.119092openalex-snapshot
Advances in respiratory syncytial virus therapeutics: A comprehensive review of small-molecule inhibitors, monoclonal antibodies, and vaccines
inferred← citeshttps://doi.org/10.1016/j.exphem.2025.104766openalex-snapshot
Assessing the impact of cell isolation method on B cell gene expression using next-generation sequencing
inferred← citeshttps://doi.org/10.1016/j.fmc.2025.03.004openalex-snapshot
Estrategias de prevención de la infección por el virus respiratorio sincitial
inferred← citeshttps://doi.org/10.1016/j.fmre.2026.04.028openalex-snapshot
Respiratory Syncytial Virus (RSV) Small-Molecule Therapeutics Sail Between Scylla and Charybdis Toward Clinical Breakthroughs
inferred← citeshttps://doi.org/10.1016/j.gendis.2026.102511openalex-snapshot
Extracellular nonstructural protein 1 of human respiratory syncytial virus during the early infection phase is associated with a TH2-related immune response, contributing to disease severity in human infants
inferred← citeshttps://doi.org/10.1016/j.gpeds.2023.100120openalex-snapshot
Along came COVID-19: The changing landscape of serious childhood infections
inferred← citeshttps://doi.org/10.1016/j.gpeds.2023.100130openalex-snapshot
Respiratory Syncytial Virus infection: New prevention strategies
inferred← citeshttps://doi.org/10.1016/j.hlife.2023.09.003openalex-snapshot
A protective human antibody against respiratory syncytial virus by targeting a prefusion epitope across sites IV and V of the viral fusion glycoprotein
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2024.134012openalex-snapshot
Revisiting the dimensions of universal vaccine with special focus on COVID-19: Efficacy versus methods of designing
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2025.145386openalex-snapshot
Ultra-potent RBM-specific single-domain antibody broadly neutralizes multiple SARS-CoV-2 variants with picomolar activity
inferred← citeshttps://doi.org/10.1016/j.ijid.2024.107118openalex-snapshot
Efficacy and safety of vaccines to prevent respiratory syncytial virus infection in infants and older adults: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.ijid.2024.107231openalex-snapshot
Seasonality and severity of respiratory syncytial virus during the COVID-19 pandemic: a dynamic cohort study
showing the first 200 of 1030
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.